

Tian'an Pharmaceutical Co Limited

A Nevada Corporation

50 West Liberty Street, Suite 880
Reno, NV 89501

Telephone: +1 3236131577
www.ninedegreesgroup.com
info@jiudugroup.com
SIC Code: 7389

Quarterly Report **For the Quarter Ending: June 30, 2022** (the "Reporting Period")

As of June 30, 2022, the number of shares outstanding of our Common Stock was: 81,725,010

As of March 31, 2022, the number of shares outstanding of our Common Stock was: 49,995,010

As of December 31, 2021, the number of shares outstanding of our Common Stock was: 49,995,010

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: No: (Double-click and select "Default Value" to check)

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: No:

1) Name and address(es) of the issuer and its predecessors (if any)

Tian'an Pharmaceutical Limited

Incorporated in the state of Nevada on August 25, 2005. Current standing: active

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

N/A

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

N/A

The address(es) of the issuer's principal executive office:

50 West Liberty Street, Suite 880, Reno, NV 89501.

¹ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past 5 years?

Yes: No:

On November 07, 2018, the eighth judicial District Court of Nevada appointed Custodian Ventures, LLC as custodian. The custodianship ended on February 12, 2019.

2) Security Information

Trading symbol: TNPH
 Exact title and class of securities outstanding: Common Stock
 CUSIP: 8863V103
 Par or stated value: US\$0.001
 Total shares authorized: 900,000,000 as of date: June 30, 2022
 Total shares outstanding: 81,725,010 as of date: June 30, 2022
 Number of shares in the Public Float: 13,995,010 as of date: June 30, 2022
 Total number of shareholders of record: 1,995 as of date: June 30, 2022

Trading symbol: N/A
 Exact title and class of securities outstanding: Preferred Stock
 Par or stated value: US\$0.001
 Total shares authorized: 50,000,000 as of date: June 30, 2022
 Total shares outstanding: 47,884,878 as of date: June 30, 2022

Transfer Agent

Name: EQ Shareowner Services
1110 Centre Pointe Curve, Suite 101
Mendota Heights, MN 55120
 Phone: 303-282-4800
 Email: cynthia.hintgen@equiniti.com

Is the Transfer Agent registered under the Exchange Act? Yes: No:

3) Issuance History

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods:

Number of Shares outstanding as of <u>1/1/2020</u>	<u>Opening Balance:</u> Common: <u>49,995,010</u> Preferred: <u>0</u>		*Right-click the rows below and select "Insert" to add rows as needed.						
<u>Date of Transaction</u>	<u>Transaction type (e.g. new issuance, cancellation, shares returned to treasury)</u>	<u>Number of Shares Issued (or cancelled)</u>	<u>Class of Securities</u>	<u>Value of shares issued (\$/per share) at Issuance</u>	<u>Were the shares issued at a discount to market price at time of issuance? (Yes/No)</u>	<u>Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).</u>	<u>Reason for share issuance (eg. for cash or debt conversion) OR Nature of Services Provided (if applicable)</u>	<u>Restricted or Unrestricted as of this filing?</u>	<u>Exemption or Registration Type?</u>
<u>2/5/2020</u>	<u>New issuance</u>	<u>45,000,000</u>	<u>Preference</u>	<u>US\$0.001</u>	<u>No</u>	<u>Simon Littlewood/Infra AG</u>	<u>Debt settlement</u>	<u>Restricted</u>	<u>144</u>
<u>5/29/2022</u>	<u>Convert Pref to Common</u>	<u>(1,101,890)</u> <u>16,530,000</u>	<u>Pref</u> <u>Common</u>	<u>US\$0.001</u>	<u>No</u>	<u>Multiple non control</u>	<u>Convert Pref to Common</u>	<u>Restricted</u>	<u>144</u>

<u>6/2/2022</u>	<u>Convert Pref to Common</u>	<u>(1,013,232)</u> <u>15,200,000</u>	<u>Pref</u> <u>Common</u>	<u>US\$0.001</u>	<u>No</u>	<u>Multiple non control</u>	<u>Convert Pref to Common</u>	<u>Restricted</u>	<u>144</u>
Shares Outstanding on <u>June 30, 2022:</u>	<u>Ending Balance:</u> Common: <u>81,725,010</u> Preferred: <u>47,884,878</u>								

B. Debt Securities, Including Promissory and Convertible Notes

Check this box if there are no outstanding promissory, convertible notes or debt arrangements:

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- U.S. GAAP
 IFRS

B. The financial statements for this reporting period were prepared by:

Name: Simon Littlewood
Title: President, Tian'an Pharmaceutical Co. Ltd.
Relationship to Issuer: President

TIAN'AN PHARMACEUTICAL CO. LTD. BALANCE SHEETS (Un-audited)

	June 30, 2022	December 31, 2021
ASSETS		
CURRENT ASSETS:		
Cash	\$ 3,102	\$ 9,761
Trade debtors	7,500	-
Other debtors	1,983	5,183
Total current assets	12,585	14,945
TOTAL ASSETS	\$ 12,585	\$ 14,945
LIABILITIES AND STOCKHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Accounts payable and accrued liabilities	35,000	20,000
Related party payable	172,467	175,568
Total current liabilities	207,467	195,568
Commitments and Contingencies		
STOCKHOLDERS' EQUITY		
Series A Preferred Stock, par value \$0.001 per share; 50,000,000 shares authorized; 50,000,000 issued and outstanding June 30, 2022 (50,000,000 31 Dec. 31, 2021)	47,885	50,000
Common stock, par value \$0.001 per share; 900,000,000 shares authorized; 81,725,010 shares issued and outstanding as of June 30, 2022 (49,995,010 Dec. 31, 2021)	81,725	49,995
Additional paid in capital	7,239,562	7,269,177
Retained earnings	(7,564,054)	(7,549,795)
Total stockholders' equity	(194,882)	(180,623)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ 12,585	\$ 14,945

The accompanying notes are an integral part of these financial statements.

TIAN'AN PHARMACEUTICAL CO. LTD.
STATEMENTS OF INCOME & OPERATIONS
(Un-audited)

	For The Three Months Ended June 30,	
	\$ 2022	\$ 2021
Sales	7,500	-
OPERATING EXPENSES:		
Consulting fees – related party	-	15,000
Professional & consulting fees	1,163	745
Administration expenses	1,390	1,769
	2,553	17,514
Interest income		
NET INCOME (LOSS)	4,947	(17,514)
Net profit (loss) per common share – basic and diluted	\$ 0.00	\$ 0.00
Weighted average common shares outstanding – basic and diluted	60,484,680	49,995,010

TIAN'AN PHARMACEUTICAL CO. LTD.
STATEMENTS OF CASH FLOWS
FOR THE PERIOD
(Un-audited)

	For the Three Months Ended June 30	
	2022	2021
OPERATING ACTIVITIES:		
Net profit/(loss)	\$ 4,947	(17,514)
Adjustments to reconcile net loss to net cash (used in) operating activities:		
Changes in assets and liabilities		
Accounts receivable	(5,900)	1,726
Shares issued to related party		
Accounts payable and accrued expenses	(989)	
NET CASH PROVIDED BY OPERATING ACTIVITIES	(1,943)	(15,288)
FINANCING ACTIVITIES		
Issue of new shares		
Reduction in share premium account		
Payments & loan to related party		
Loans from related parties	(4,717)	15,288
NET CASH PROVIDED BY FINANCING ACTIVITIES	(4,717)	15,288
NET (DECREASE)/INCREASE IN CASH	(6,660)	-
CASH – BEGINNING OF PERIOD	9,761	15,000
CASH – END OF PERIOD	\$ 3,102	15,000

The accompanying notes are an integral part of these financial statements.

TIAN'AN PHARMACEUTICAL CO. LTD.
STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY
(Un-audited)

	Common Stock		Preferred Stock		Additional Paid In Capital	Retained Earnings	Total
	Shares	Amount	Shares	Amount			
Balances At Dec 31, 2019	49,995,010	\$49,995	5,000,000	5,000			
Issue of Pref. Shares			45,000,000	45,000			45,000
Loss for the period						(27,627)	(27,627)
At Mar 31, 2020	49,995,010	\$49,995	50,000,000	50,000	7,269,177	(7,465,952)	(96,780)
Loss for period						(18,198)	(18,198)
At June 30, 2020	49,995,010	\$49,995	50,000,000	50,000	7,269,177	(7,484,150)	(114,978)
Loss for period						(16,602)	(16,602)
At Sep. 30, 2020	49,995,010	\$49,995	50,000,000	50,000	7,269,177	(7,500,752)	(131,580)
Loss for period						(17,648)	(17,648)
Balance At Dec. 31, 2020	49,995,010	\$49,995	50,000,000	50,000	7,269,177	(7,518,400)	(149,228)
Loss for period						(4,152)	(4,152)
At Mar. 31, 2021	49,995,010	\$49,995	50,000,000	50,000	7,269,177	(7,522,552)	(153,380)
Loss for period						(17,514)	(17,514)
At June 30, 2021	49,995,010	\$49,995	50,000,000	50,000	7,269,177	(7,540,066)	(170,894)
Loss for period						(2,481)	(2,481)
At 30 Sep 2021	49,995,010	\$49,995	50,000,000	50,000	7,269,177	(7,542,547)	(173,375)
Loss for period						(7,249)	(7,249)
At Dec. 31, 2021	49,995,010	\$49,995	50,000,000	50,000	7,269,177	(7,549,795)	(180,624)
Loss for period						(19,205)	(19,205)
At Mar. 31, 2022	49,995,010	\$49,995	50,000,000	50,000	7,269,177	(7,569,001)	(199,829)
Profit for period						4,947	4,947
Conversion of Pref Shares	31,730,000	31,730	(2,115,122)	(2,115)	(29,615)		-
At June 30, 2022	49,995,010	\$81,725	47,884,878	47,885	7,239,562	(7,564,054)	(194,882)

The accompanying notes are an integral part of these financial statements.

TIAN'AN PHARMACEUTICAL CO. LTD.
NOTES TO FINANCIAL STATEMENTS
FOR THE QUARTER TO JUNE 30, 2022 and DECEMBER 31, 2021

Note 1 – Organization and basis of accounting

Basis of Presentation and Organization

Tian'an Pharmaceutical Co Ltd. (the "**Company**") was established in Nevada in August 2005. The Company invests, advises and builds businesses in the health and wellness, education, food and agriculture, fintech, e-commerce, tourism and consumer sectors.

On November 07, 2018, the eighth judicial District Court of Nevada appointed Custodian Ventures, LLC as custodian for the Company. On November 12, 2018, the Company issued 36,000,000 shares of common stock to Custodian Ventures, LLC at par for shares valued at \$36,000 in exchange for settlement of a portion of a related party loan for amounts advanced to the Company in the amount of \$16,300, in addition to a demand note issued to the Company in the amount \$19,700. On November 14, 2018, the Company issued 5,000,000 shares of series A preferred stock to Custodian Ventures, LLC at par for shares valued at \$5,000 in exchange for settlement of a portion of the related party loan in the amount of \$5,000.

On February 01, 2019, Custodian Ventures LLC (the "Seller"), entered into a Stock Purchase Agreement (the "Stock Purchase Agreement") pursuant to which the Seller agreed to sell to Springview Inc and Infra AG (together, the "Purchaser"), the 36,000,000 common shares and the 5,000,000 preferred shares of the Company (together, the "Shares") owned by the Seller, for a total purchase price of \$180,000. As a result of the sale, and David Lazar's resignation as sole officer and director of the Company, there was a change of control of the Company. There is no family relationship or other relationship between the Seller and the Purchaser. On February 5, 2020 the Company issued 45 million preferred shares at par for US\$45,000 to Infra AG and Simon Littlewood in partial settlement of amounts owed.

The accompanying financial statements are prepared on the basis of accounting principles generally accepted in the United States of America ("GAAP"). The Company is a development stage enterprise devoting substantial efforts to establishing a new business, financial planning, raising capital, and research into products which may become part of the Company's product portfolio. The Company has not realized significant sales. A development stage company is defined as one in which all efforts are devoted substantially to establishing a new business and, even if planned principal operations have commenced, revenues are insignificant.

The accompanying financial statements have been prepared assuming the continuation of the Company as a going concern. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and is dependent on debt and equity financing to fund its operations. Management of the Company is making efforts to raise additional funding until a registration statement relating to an equity funding facility is in effect. While management of the Company believes that it will be successful in its capital formation and planned operating activities, there can be no assurance that the Company will be able to raise additional equity capital, or be successful in the development and commercialization of the products it develops or initiates collaboration agreements thereon. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

Note 2 – Summary of significant accounting policies

Cash and Cash Equivalents

For purposes of reporting within the statements of cash flows, the Company considers all cash on hand, cash accounts not subject to withdrawal restrictions or penalties, and all highly liquid debt instruments purchased with a maturity of three months or less to be cash and cash equivalents.

Income Taxes

The Company accounts for income taxes pursuant to FASB ASC Topic 740, *Income Taxes*. Under FASB ASC Topic 740, deferred tax assets and liabilities are determined based on temporary differences between the bases of certain assets and liabilities for income tax and financial reporting purposes. The deferred tax assets and liabilities are classified according to the financial statement classification of the assets and liabilities generating the differences.

The Company maintains a valuation allowance with respect to deferred tax assets. The Company establishes a valuation allowance based upon the potential likelihood of realizing the deferred tax asset and taking into consideration the Company's financial position and results of operations for the current period. Future realization of the deferred tax benefit depends on the existence of sufficient taxable income within the carry-forward period under the Federal tax laws.

Changes in circumstances, such as the Company generating taxable income, could cause a change in judgment about the reliability of the related deferred tax asset. Any change in the valuation allowance will be included in income in the year of the change in estimate.

Employee Stock-Based Compensation

The Company accounts for stock-based compensation in accordance with ASC 718 Compensation - Stock Compensation (“ASC 718”). ASC 718 addresses all forms of share-based payment (“SBP”) awards including shares issued under employee stock purchase plans and stock incentive shares. Under ASC 718 awards result in a cost that is measured at fair value on the awards’ grant date, based on the estimated number of awards that are expected to vest and will result in a charge to operations.

Estimates

The financial statements are prepared on the basis of accounting principles generally accepted in the United States of America. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of December 31, 2021 and December 31, 2020, and expenses for the year ended December 31, 2021 and 2020, and cumulative from inception. Actual results could differ from those estimates made by management.

Subsequent Event

The Company evaluated subsequent events through the date when financial statements are issued for disclosure consideration.

Recent Accounting Pronouncements

The Company believes it has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Note 3 – Related party transaction

On February 01, 2019, Custodian Ventures LLC (the “Seller”), entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) pursuant to which the Seller agreed to sell to Springview Inc and Infra AG (together, the “Purchaser”), the 36,000,000 common shares and the 5,000,000 preferred shares of the Company (together, the “Shares”) owned by the Seller, for a total purchase price of \$180,000. As a result of the sale, and David Lazar’s resignation as sole officer and director of the Company, there was a change of control of the Company. There is no family relationship or other relationship between the Seller and the Purchaser.

During the year ended December 31, 2021, Simon Littlewood, President of the Company, and related parties advanced a total of \$5,980 (2020 \$18,719) to the Company for payment of accounting, legal, OTC fees and for administration expenses. During the year ended December 31, 2021, companies associated with the Company’s President, Simon Littlewood, invoiced \$15,000 (2019 \$60,000) for services and expenses incurred. As of June 30, 2022 a total of \$172,467 (Dec 31, 2021: \$175,568) remained outstanding to companies associated with the President and to the President. These loans are unsecured, non-interest bearing, and have no specific terms for repayment. On February 5, 2020 the Company issued 45,000,000 preferred shares at par for US\$45,000 to companies associated with the President and to the President in satisfaction of part of the debts owed.

Note 4 – Stockholders Equity

Common Stock

On November 12, 2018, the Company issued 36,000,000 shares of common stock to Custodian Ventures, LLC at par for shares valued at \$36,000 in exchange for settlement of a portion of the related party loan in the amount of \$16,300 and a demand note issued to the Company in the amount \$19,700.

31,730,000 shares were issued between May 29 and June 2, 2022 following the conversion of Preference Shares (see below)

Preferred Stock

On November 13, 2018 the Company created 5,000,000 shares of Series A Preferred Stock, out of the 20,000,000 shares that were already authorized. On November 14, 2018, the Company issued 5,000,000 shares of series A Preferred stock to Custodian Ventures, LLC at par for shares valued at \$5,000 in exchange for settlement of a portion of the related party loan in the amount of \$5,000.

On February 5, 2020 the Company issued 45,000,000 preferred shares at par to companies associated with the President and to the President in satisfaction of part of the debts owed to them.

On May 29, 2022 1,101,890 Preference Stock were converted, resulting in the issue of 16,530,000 common stock. On June 2, 2022 1,013,232 Preference Shares were converted, resulting in the issue of 15,200,000 common stock.

The following is a description of the material rights of our Series A Preferred Stock:

Each share of Series A Preferred Stock shall have a par value of \$0.001 per share. The Series A Preferred Stock shall vote on any matter that may from time to time be submitted to the Company's shareholders for a vote, on a one for one basis. If the Company effects a stock split which either increases or decreases the number of shares of Common Stock outstanding and entitled to vote, the voting rights of the Series A shall not be subject to adjustment unless specifically authorized.

Each share of Series A Preferred Stock shall be convertible at a price of per share \$0.00006666 shares of Common Stock ("Conversion Ratio"), at the option of a Holder, at any time and from time to time, from and after the issuance of the Series A Preferred Stock. Subject to the rights of any existing series of Preferred Stock or to the rights of any series of Preferred Stock which may from time to time hereafter come into existence, the holders of shares of Series A Preferred Stock shall be entitled to receive dividends, out of any assets legally available therefor, upon any payment of any dividend (payable other than in Common Stock or other securities and rights convertible into or entitling the holder thereof to receive, directly or indirectly, additional shares of Common Stock of the Corporation) on the Common Stock of the Corporation, as and if declared by the Board of Directors, as if the Series A Preferred Stock had been converted into Common Stock.

In the event of any liquidation, dissolution or winding up of the Corporation, either voluntary or involuntary, subject to the rights of any existing series of Preferred Stock or to the rights of any series of Preferred Stock which may from time to time hereafter come into existence, the holders of the Series A Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of the assets of the Corporation to the holders of Common Stock by reason of their ownership thereof, an amount per share equal to the price per share actually paid to the Corporation upon the initial issuance of the Series A Preferred Stock (each, the "the Original Issue Price") for each share of Series A Preferred Stock then held by them, plus declared but unpaid dividends. Unless the Corporation can establish a different Original Issue Price in connection with a particular sale of Series A Preferred Stock, the Original issue price shall be \$0.001 per share for the Series A Preferred Stock. If, upon the occurrence of any liquidation, dissolution or winding up of the Corporation, the assets and funds thus distributed among the holders of the Series A Preferred Stock shall be insufficient to permit the payment to such holders of the full aforesaid preferential amounts, then, subject to the rights of any existing series of Preferred Stock or to the rights of any series of Preferred Stock which may from time to time hereafter come into existence, the entire assets and funds of the corporation legally available for distribution shall be distributed ratably among the holders of the each series of Preferred Stock in proportion to the preferential amount each such holder is otherwise entitled to receive.

The Series A Preferred Stock shares are nonredeemable other than upon the mutual agreement of the Company and the holder of shares to be redeemed, and even in such case only to the extent permitted by this Certificate of Designation, the Corporation's Articles of Incorporation and applicable law. Series A Preferred Stock shall be convertible, at the option of the holder thereof, at any time after the date of issuance of such share, at the office of the Corporation or any transfer agent for such stock, into such number of fully paid and non-assessable shares of Common Stock as is determined by dividing the Original Issue Price of the Series A Preferred Stock by the Series A Conversion Price applicable to such share, determined as hereafter provided, in effect on the date the certificate is surrendered for conversion. Each share of Series A Preferred Stock shall automatically be converted into shares of Common Stock at the applicable Series A Conversion Price in effect for such share immediately upon the earlier of (i) except as provided below in Section 4(c), the Corporation's sale of its Common Stock in a public offering pursuant to a registration statement under the Securities Act of 1933, as amended; (ii) a liquidation, dissolution or winding up of the Corporation as defined in section 2(c) above but subject to any liquidation preference required by section 2(a) above; or (iii) the date specified by written consent or agreement of the holders of a majority of the then outstanding shares of Series A Preferred Stock.

5) Issuer's Business, Products and Services

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

The Company makes investments in and advises businesses in the health and wellness, fintech, education, food and agriculture, e-commerce and consumer sectors.

B. Please list any subsidiaries, parents, or affiliated companies.

The Company has a 100% stake in Hong Kong incorporated JiuDu International Ltd ("**JiuDu HK**"). JiuDu HK is currently performing due diligence on a number of potential investments and acquisitions in Greater China.

The Company is affiliated with Infra Ag., which is controlled by Simon Littlewood, who is CEO of Infra AG and President of the Company. Infra Ag. is registered at Kandelstrasse 9 79206 Breisach am Rhein, Germany.

C. Describe the issuers' principal products or services

The Company invests in and builds businesses in the health and wellness, fintech, education, agriculture and food, e-commerce and consumer sectors. The Company is currently performing due diligence on two businesses in southern China, one in the health sector and one in e-commerce, with a view to making investments in them.

It is anticipated to complete the investment in one of the businesses in the next few months. The acquisition will be primarily via the issue of shares by the Company.

6) Issuer's Facilities

The Company currently has no operating facilities nor fixed assets

7) Company Insiders (Officers, Directors, and Control Persons)

As at June 30, 2022:

Name of Officer/Director and Control Person	Affiliation with Company (e.g. Officer/Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
Simon Littlewood	Director	Reno, Nevada	16,051,500	Common Stock	19.6%	(a)
Ping Shun Ngan	Shareholder & Director of subsidiary	Hong Kong, China	4,950,000	Common Stock	6.1%	
Biao Su	Shareholder	Guilin, Guangxi Province, China	4,999,500	Common Stock	6.1%	
JiuDu Tianan TNPH Holdings International Group Co. Ltd	Shareholder	Hong Kong, China	9,999,000	Common Stock	12.2%	(b)
Simon Littlewood	Director	Reno, Nevada	47,884,878	Preferred Stock	100%	(c)

(a) Shares are held by companies controlled by S Littlewood and his associates

(b) Mr Ngan is a shareholder and director.

(c) Held by companies controlled by S Littlewood and his associates.

8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

N/A

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

N/A

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

N/A

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

N/A

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

N/A

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: Matthew McMurdo
Firm: McMurdo Law Group LLC
Address 1: 1185 Avenue of Americas, 3rd Floor
Address 2: New York NY 10036
Phone: 917 318 2865
Email: matt@nannaronelaw.com

10) Issuer Certification

Principal Executive Officer:

I, Simon Littlewood certify that:

1. I have reviewed this quarterly disclosure statement of Tian'an Pharmaceutical Co Ltd;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 14, 2022

Simon Littlewood, President

Principal Financial Officer

I, Simon Littlewood certify that:

1. I have reviewed this quarterly disclosure statement of Tian'an Pharmaceutical Co Ltd;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 14, 2022

Simon Littlewood, Chief Financial Officer